Posted on

Eli Lilly gets the Go for its Monoclonal Antibody Cocktail for “mild to moderate” COVID-19

external content.duckduckgo 1

the staff of the Ridgewood blog

Ridgewood NJ, according to Johns Hopkins Center for Health Security on February 9, the US FDA issued an Emergency Use Authorization (EUA) for Eli Lilly’s monoclonal antibody cocktail of bamlanivimab and etesevimab as a treatment for COVID-19. The EUA specifically authorizes the treatment for “mild to moderate” COVID-19 in adults and pediatric patients aged 12 years and older who are “at high risk for progressing to severe” disease.

Bamlaminivab was previously authorized for use under its own EUA. Under the new EUA, the two monoclonal antibodies are administered together in a single infusion, and the new EUA allows for infusion times as short as 16 minutes, which is less than a third of the time required for previous infusions. Like bamlanivimab by itself, the combination therapy can be administered as long as 10 days after symptom onset, but it is recommended to start treatment as soon as possible. The new EUA gives clinicians another outpatient option for treating individuals who are not ill enough to require hospitalization, which can reduce the burden on hospitals and health systems. According to a report from The New York Times, the FDA updated the EUA for bamlanivimab by itself to shorten its infusion time as well. The shortened infusion times are a result of feedback from clinicians, and the shorter time is expected to improve access and use of the treatments.

ELI LILLY monoclonal antibody treatment for COVID Shows Promise

Valley Hospital Offering Leading-Edge Antibody Therapy for COVID-19

Regeneron COVID Antibody Treatment Gets Emergency Use Authorization from the FDA

Leave a Reply

Your email address will not be published. Required fields are marked *